Pfizer

U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication
U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication
Reuters
Pfizer
Supreme Court
Medicare
kickbacks
Vyndaqel
Vyndamax
Flag link:
JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says
JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says
Fierce Pharma
JPMHC 2023
Pfizer
Pharma CEOs
Albert Bourla
Flag link:
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
BioPharma Dive
JPMHC 2023
vaccines
COVID-19
Moderna Therapeutics
Pfizer
Gilead Sciences
Flag link:
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
Endpoints
FDA
priority review
Pfizer
Prevnar 20
vaccines
Roche
bispecific antibodies
glofitamab
lymphoma
Flag link:
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Fierce Pharma
Pfizer
Merck
JNJ
Novo Nordisk
AstraZeneca
Flag link:
Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up for sale
Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up for sale
Fierce Biotech
Pfizer
R&D
externalization
gene therapy
Rare Diseases
Flag link:
Moderna sprints toward RSV podium behind GSK, Pfizer, with eyes on combo vax
Moderna sprints toward RSV podium behind GSK, Pfizer, with eyes on combo vax
Fierce Biotech
Moderna Therapeutics
RSV
GSK
Pfizer
vaccines
Flag link:
The biggest-selling pharma companies of 2023
The biggest-selling pharma companies of 2023
EP Vantage
Pfizer
Merck
JNJ
Novartis
AbbVie
Roche
Flag link:
Astellas loses bid to block Lexiscan generics in US
Astellas loses bid to block Lexiscan generics in US
Pharmaphorum
legal
Astellas
Pfizer
Lexiscan
patents
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine
Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine
Fierce Biotech
Valneva
Pfizer
BioNTech
vaccines
boosters
COVID-29
Flag link:
Pfizer says hemophilia B gene therapy controlled bleeding in key study
Pfizer says hemophilia B gene therapy controlled bleeding in key study
BioPharma Dive
Pfizer
gene therapy
hemophilia B
fidanacogene elaparvovec
Flag link:
FDA accepts BLA for Pfizer’s meningococcal vaccine candidate
FDA accepts BLA for Pfizer’s meningococcal vaccine candidate
Pharmaceutical Business Review
Pfizer
FDA
vaccines
meningococcal disease
MenABCWY
Flag link:
Pfizer Doubles Down on AI/ML to Bring Transformative Medicines to Patients
Pfizer Doubles Down on AI/ML to Bring Transformative Medicines to Patients
BioSpace
Pfizer
artificial intelligence
machine learning
innovation
Flag link:
Pfizer advances diabetes, obesity drug hopeful into mid-stage testing
Pfizer advances diabetes, obesity drug hopeful into mid-stage testing
BioPharma Dive
Pfizer
diabetes
obesity
PF-07081532
Sosei Heptares
Flag link:
Big pharma’s new year catalysts
Big pharma’s new year catalysts
EP Vantage
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
Flag link:
Pfizer's Supreme Court challenge of US kickback law is 'far-fetched,' HHS says
Pfizer's Supreme Court challenge of US kickback law is 'far-fetched,' HHS says
Fierce Pharma
Pfizer
legal
kickbacks
Supreme Court
rebates
Medicare
Flag link:
Lilly and Pfizer fight for new territory in obesity and diabetes
Lilly and Pfizer fight for new territory in obesity and diabetes
EP Vantage
Eli Lilly
Pfizer
obesity
diabetes
orforglipron
Mounjaro
Flag link:
Biopharma’s 5 Biggest M&A Deals of 2022
Biopharma’s 5 Biggest M&A Deals of 2022
BioSpace
M&A
Amgen
Horizon Therapeutics
Pfizer
Biohaven
Global Blood Therapeutics
Bristol Myers Squibb
Turning Point Therapeutics
ChemoCentryx
Flag link:
Pfizer's plan for $110+ Covid-19 vaccines riles up US senators
Pfizer's plan for $110+ Covid-19 vaccines riles up US senators
Endpoints
Pfizer
COVID-19
vaccines
drug pricing
Senate
Flag link:

Pages